-Advertisement-
-Advertisement-
Home
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
Progressive Familial Intrahepatic Cholestasis

Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
Ipsen and Albireo announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases. The anticipated acquisition will enrich Ipsen’s Rare Disease portfolio and pipeline. The lead medicine in Albireo’s pipeline...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
Quizzes
-Advertisement-
Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 MedJournal 360® is a trademark of International Healthcare Media, LLC. All rights Reserved